<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Micromet Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/micromet-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(MITI) Micromet Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/12/09/miti-micromet-analyst-maintains-neutral-on-shares-2/88278</link>
		<comments>http://www.stockbloghub.com/2011/12/09/miti-micromet-analyst-maintains-neutral-on-shares-2/88278#comments</comments>
		<pubDate>Fri, 09 Dec 2011 17:40:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88278</guid>
		<description><![CDATA[We have maintained a Neutral rating on Micromet, Inc. (MITI) with a target price of $7.00 per share following appraisal of third quarter 2011 results. Micromet’s third quarter 2011 loss per share came in at 21 cents (after adjusting for the change in fair value of warrants), wider than the year-ago loss of 13 cents per share (also adjusting for the change in fair value of warrants). Lower-than-expected revenues led to the wider loss in the quarter. Revenues at Micromet were down almost 33% from the prior-year period to $4.5 million in the third quarter of 2011 due to lower collaboration revenue. Moreover, revenues in the year-ago quarter were boosted by the presence of a milestone payment from AstraZeneca (AZN). Revenues were also much below the Zacks Consensus Estimate of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/09/miti-micromet-analyst-maintains-neutral-on-shares-2/88278/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MITI) Micromet Begins New Trial</title>
		<link>http://www.stockbloghub.com/2011/12/06/miti-micromet-begins-new-trial/88072</link>
		<comments>http://www.stockbloghub.com/2011/12/06/miti-micromet-begins-new-trial/88072#comments</comments>
		<pubDate>Tue, 06 Dec 2011 19:36:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CR]]></category>
		<category><![CDATA[Crane Company]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88072</guid>
		<description><![CDATA[Micromet Inc. (MITI) recently announced that it has begun a mid-stage registrational trial of its lead pipeline candidate, blinatumomab, in adult patients with B-precursor relapsed refractory acute lymphoblastic leukemia (ALL). The trial was advised to be conducted by the US Food &#38; Drug Administration (FDA) to support accelerated approval of blinatumomab. The trial is a single-arm study which will evaluate 65 patients with the primary endpoint of complete remission (CR) or CR with partial recovery of blood counts (CRh). Micromet expects to complete enrollment for the trial by year-end 2012. The mid-stage study will be followed by a late-stage trial (with a time dependent endpoint) to evaluate the safety and efficacy of blinatumomab versus chemotherapy in adult patients with relapsed refractory B precursor ALL. Design details of the late-stage trial ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/06/miti-micromet-begins-new-trial/88072/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MITI) Micromet Loss Less Than Analyst Estimates &#8211; Revenues Rise</title>
		<link>http://www.stockbloghub.com/2011/08/09/miti-micromet-loss-less-than-analyst-estimates-revenues-rise/80906</link>
		<comments>http://www.stockbloghub.com/2011/08/09/miti-micromet-loss-less-than-analyst-estimates-revenues-rise/80906#comments</comments>
		<pubDate>Tue, 09 Aug 2011 19:31:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CR]]></category>
		<category><![CDATA[Crane Company]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80906</guid>
		<description><![CDATA[Micromet Inc.’s (MITI) second quarter 2011 loss per share came in at 19 cents (after adjusting for the change in fair value of warrants), wider than the year-ago loss of 15 cents per share (also adjusting for the change in fair value of warrants). The loss was, however, narrower than the Zacks Consensus Estimate of a loss of 21 cents due to higher-than-expected revenues. Loss widened from the prior year due to higher operating expenses which more than offset the rise in revenues. Quarterly Details Revenues at Micromet were up 7.8% to $7.1 million in the second quarter of 2011 on the back of higher collaboration revenue. Revenues were also above the Zacks Consensus Estimate of $6 million. Operating expenses during the reported quarter climbed approximately 56% over the prior-year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/09/miti-micromet-loss-less-than-analyst-estimates-revenues-rise/80906/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MITI) Micromet Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/07/06/miti-micromet-analyst-maintains-neutral-on-shares/78499</link>
		<comments>http://www.stockbloghub.com/2011/07/06/miti-micromet-analyst-maintains-neutral-on-shares/78499#comments</comments>
		<pubDate>Wed, 06 Jul 2011 21:17:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78499</guid>
		<description><![CDATA[We have maintained a Neutral rating on Micromet, Inc. (MITI) with a target price of $6.00 per share. We believe Micromet’s lead pipeline candidate, blinatumomab, holds tremendous potential in the treatment of Acute lymphoblastic leukemia (ALL). Blinatumomub is one of the leading BiTE antibodies. BiTE antibodies represent a new class of antibodies that activate the T-cells of a patient’s immune system to eliminate cancer cells. The company is conducting a pivotal study of blinatumomab (MT103) in Europe in adults with minimal residual disease (MRD) positive B-precursor acute lymphoblastic leukemia (ALL), also referred to as front-line ALL. The company also has a mid-stage study (n=20) of blinatumomab underway in adults suffering from relapsed or refractory B-precursor ALL. Micromet has presented encouraging data from both trials. We believe the successful development and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/06/miti-micromet-analyst-maintains-neutral-on-shares/78499/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SNY) Sanofi-Aventis Announces Agreement to Acquire TargaGen</title>
		<link>http://www.stockbloghub.com/2010/07/01/sny-sanofi-aventis-announces-agreement-to-acquire-targagen/42058</link>
		<comments>http://www.stockbloghub.com/2010/07/01/sny-sanofi-aventis-announces-agreement-to-acquire-targagen/42058#comments</comments>
		<pubDate>Thu, 01 Jul 2010 16:50:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[EXEL]]></category>
		<category><![CDATA[Exelixis Inc]]></category>
		<category><![CDATA[MF]]></category>
		<category><![CDATA[MF Global Ltd]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>
		<category><![CDATA[Regeneron Pharmaceuticals Inc]]></category>
		<category><![CDATA[REGN]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=42058</guid>
		<description><![CDATA[Sanofi-Aventis (SNY) continues to work on expanding its oncology portfolio with the company recently entering into an agreement to acquire TargaGen Inc. TargaGen, a privately-held US biopharmaceutical company, is focused on the development of candidates for the treatment of certain types of leukemia, lymphoma and other hematological malignancies and blood disorders. Deal Could be Worth $560M Per the terms of the agreement, TargaGen will receive $75 million once the transaction closes. Sanofi will make additional payments on the achievement of development milestones. Including the $75 million upfront payment, Sanofi could end up paying up to $560 million. The deal is scheduled to close in the third quarter of 2010. Deal to Expand Oncology Pipeline TargaGen’s lead pipeline candidate, TG101348, is an oral agent that is being developed for the treatment ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/01/sny-sanofi-aventis-announces-agreement-to-acquire-targagen/42058/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MITI) Micromet&#8217;s Quarterly Report Shows Loss Increase</title>
		<link>http://www.stockbloghub.com/2010/05/06/miti-micromets-quarterly-report-shows-loss-increase/36422</link>
		<comments>http://www.stockbloghub.com/2010/05/06/miti-micromets-quarterly-report-shows-loss-increase/36422#comments</comments>
		<pubDate>Thu, 06 May 2010 20:35:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=36422</guid>
		<description><![CDATA[Micromet’s (MITI) first quarter fiscal 2010 loss per share came in at 23 cents, greater than the year-ago quarter’s loss of a penny. However, after adjusting for the change in fair value of warrants, the company reported a loss per share of 15 cents, better than the Zacks Consensus Estimate of a loss of 17 cents. Post adjustment, the year-ago quarter posted a loss of 9 cents. Micromet reported revenues of $6.3 million compared with $7.5 million in the first quarter of 2009. The company records revenues primarily in the form of reimbursement of expenses incurred by it under different collaborative agreements. . Operating expenses during the reported quarter increased 40% year over year to $17.4 million. Research and development ($12.2 million) and general and administrative ($5.22 million) expenses increased ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/06/miti-micromets-quarterly-report-shows-loss-increase/36422/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MITI) Micromet Announces 10 Million Share Stock Offering</title>
		<link>http://www.stockbloghub.com/2010/03/10/miti-micromet-announces-10-million-share-stock-offering/30311</link>
		<comments>http://www.stockbloghub.com/2010/03/10/miti-micromet-announces-10-million-share-stock-offering/30311#comments</comments>
		<pubDate>Thu, 11 Mar 2010 02:54:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30311</guid>
		<description><![CDATA[Recently, Micromet (MITI) announced a 10 million share offering of common stock. In Aug 2009, Micromet received net proceeds of about $75 million from a common stock issuance. We believe with the advancement of clinical trials, the company’s R&#38;D costs are expected to increase further, hence the need to raise funds. Due to the funds raised during the third quarter, Micromet exited 2009 with $113.4 million in cash and cash equivalents, up from $46 million at the end of Dec 2008. Micromet does not have any marketed products at present and records revenues in the form of licensing fees, milestone payments and fees for research services earned from license agreements or from research and development collaboration agreements. Blinatumomab, the main pipeline candidate at Micromet is being studied for indications such ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/10/miti-micromet-announces-10-million-share-stock-offering/30311/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MITI) Micromet&#8217;s Fourth Quarter Loss Greater Than Expectations</title>
		<link>http://www.stockbloghub.com/2010/03/05/miti-micromets-fourth-quarter-loss-greater-than-expectations/29865</link>
		<comments>http://www.stockbloghub.com/2010/03/05/miti-micromets-fourth-quarter-loss-greater-than-expectations/29865#comments</comments>
		<pubDate>Fri, 05 Mar 2010 19:03:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29865</guid>
		<description><![CDATA[Micromet’s (MITI) fourth quarter loss per share came in at 34 cents, wider than the Zacks Consensus Estimate of 18 cents and a loss of 12 cents reported in the prior-year period. For 2009, the company reported a loss per share of 98 cents compared to a loss of 77 cents in 2008. Micromet reported revenues of $4.6 million compared to $5.8 million in the fourth quarter of 2008. The company records revenues primarily in the form of reimbursement of expenses incurred by it under different collaborative agreements. For the full year, revenues came in at $21 million, down 23% from $27.3 million in 2008. Operating expenses during the reported quarter increased 130% year-over-year to $28.3 million primarily due to $13.3 million as one-time charges. The charges relate to the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/05/miti-micromets-fourth-quarter-loss-greater-than-expectations/29865/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MITI) Micromet Incorporated &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2010/01/29/miti-micromet-incorporated-bear-of-the-day/26402</link>
		<comments>http://www.stockbloghub.com/2010/01/29/miti-micromet-incorporated-bear-of-the-day/26402#comments</comments>
		<pubDate>Sat, 30 Jan 2010 01:00:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26402</guid>
		<description><![CDATA[Micromet&#8217;s (MITI) third quarter loss per share came in at $0.22, wider than the Zacks Consensus Estimate of $0.14. Micromet&#8217;s re-acquisition of blinatumomab rights from MedImmune is of great significance as the company will be able to re-license the drug at more attractive terms. We believe that the company requires the strength of a large established player to accelerate blinatumomab&#8217;s clinical development that seems crucial in order to gain a head-start over potential competitors. Although no treatment options targeting CD19 are currently available commercially, many companies have pipeline candidates targeting it. Given the uncertainty related to its early stage pipeline, we downgrade the stock to Underperform. Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/29/miti-micromet-incorporated-bear-of-the-day/26402/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MITI) Micromet&#8217;s Pipeline Impresses</title>
		<link>http://www.stockbloghub.com/2009/12/30/miti-micromets-pipeline-impresses/23917</link>
		<comments>http://www.stockbloghub.com/2009/12/30/miti-micromets-pipeline-impresses/23917#comments</comments>
		<pubDate>Wed, 30 Dec 2009 21:37:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23917</guid>
		<description><![CDATA[We have been waiting for final phase II data on Micromet’s (MITI) lead pipeline candidate blinatumomab, which was presented earlier this month at the American Society of Hematology (ASH) meeting. The company’s product pipeline consists of novel antibodies generated with the proprietary bispecific T-cell engager (BiTE) antibody platform, as well as conventional monoclonal antibodies. The data is from a phase II clinical trial of the drug that was conducted with patients suffering from B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is a recombinant single-chain BiTE molecule targeting a protein called CD19, which is highly expressed in cancer cells. However, no treatment targeting CD19 is currently commercially available. Patients with ALL are typically treated with complex and highly toxic chemotherapy regimens, which may be followed by bone marrow stem cell transplantation for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/30/miti-micromets-pipeline-impresses/23917/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MITI) Micromet &amp; Bayer Take a BiTE</title>
		<link>http://www.stockbloghub.com/2009/12/02/miti-micromet-bayer-take-a-bite/21804</link>
		<comments>http://www.stockbloghub.com/2009/12/02/miti-micromet-bayer-take-a-bite/21804#comments</comments>
		<pubDate>Wed, 02 Dec 2009 22:20:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21804</guid>
		<description><![CDATA[Micromet (MITI), a biopharmaceutical company, is dependent on many of its collaborating partners for its product portfolio. In this respect, the company received good news with Bayer exercising its option to develop a new bispecific T-cell engager (BiTE) antibody for the treatment of solid tumors. Bayer has exercised its option under the terms of the collaboration and license agreement entered in January 2009. Following this move by Bayer, both companies will be developing the drug under a formal collaboration. Micromet will be primarily responsible for the preclinical development of the BiTE antibody through the completion of phase 1 clinical trials. Thereafter, responsibility of the drug lies with Bayer, which will assume full control regarding its further development and commercialization. As per the deal, Micromet will receive an option exercise fee ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/02/miti-micromet-bayer-take-a-bite/21804/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MITI) Micromet Misses Estimates</title>
		<link>http://www.stockbloghub.com/2009/11/09/miti-micromet-misses-estimates/20050</link>
		<comments>http://www.stockbloghub.com/2009/11/09/miti-micromet-misses-estimates/20050#comments</comments>
		<pubDate>Mon, 09 Nov 2009 22:45:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Micromet Inc]]></category>
		<category><![CDATA[MITI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20050</guid>
		<description><![CDATA[Micromet’s (MITI) third-quarter loss per share came in at 22 cents, well below the Zacks Consensus Estimate of 14 cents and a loss of 15 cents in the prior-year period. The company reported revenues of $4 million, compared to $7 million in the third quarter of 2008. Micromet records revenues primarily in the form of reimbursements of expenses incurred by the company under different collaborative agreements. We believe current investor focus is more on the developments of the company’s portfolio rather than the financials. Operating expenses during the quarter increased 28% year over year to $17.13 million, primarily due to a 34% rise in R&#38;D expenses. The increase in R&#38;D expenses was driven by Micromet assuming full responsibility of the development of its lead candidate blinatumomab as per the company’s ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/09/miti-micromet-misses-estimates/20050/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

